Genesis of arrhythmia in the course of COVID-19

Lukasz Szarpak¹,², Michal Pruc³, Anatoliy Maslyukov⁴,⁵, Mihajlo T. Glamcevski⁴,⁶, Natasza Gilis-Malinowska⁷, Miłosz J. Jaguszewski⁷

¹Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States
²Institute of Outcomes Research, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland
³Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland
⁴School of Medicine, International European University, Kyiv, Ukraine
⁵Department of Biomedical Sciences, Odessa International Medical University, Odessa, Ukraine
⁶Royal University of Phnom Penh, Phnom Penh, Cambodia
⁷¹st Department of Cardiology, Medical University of Gdansk, Poland

The paper was guest edited by Prof. Togay Evrin

Coronavirus disease 2019 (COVID-19) is associated with severe acute respiratory syndrome (SARS) this connection and effect has been exacerbated by the new strain of coronavirus (SARS-CoV-2) which has rapidly spread across the globe, posing a significant medical challenge [1, 2]. An analysis of various national health records demonstrates that many COVID-19 patients develop cardiac arrhythmias as the disease progresses. Several studies have found that these aberrant rhythms worsen the medical outcome of patients with COVID-19. However, the current medical science is unclear as to how SARS-CoV-2 infection might generate such arrhythmias [3].

The arrhythmia in COVID-19 may occur due to a large range of causes such as damage to the heart muscle, myocardial ischemia as well as in the case of myocarditis [4]. Arrhythmia can also occur in patients who have hypoxia, septic or cardiogenic shock, indications of broad systemic inflammation, or electrolyte problems such as hypokalemia. In addition, in the case of treatment of remdesivir for COVID-19, some cardiac arrhythmias have been documented [5]. Arrhythmias in the course of COVID-19 are a serious problem that occurs both in hospitalized patients and in convalescents who have already had the disease.

Tachycardia is a common symptom reported in COVID-19 patients, from their electrocardiogram results. However, recent reports have demonstrated that bradycardia is prevalent in up to 56% of hospitalized COVID-19 patients with a fever [6]. There is growing evidence and medical investigations suggesting that SARS-CoV-2 is able to infect the specialized cardiac cells known as pacemaker cells.

In healthy individuals, the primary pacemaker of the heart is the sinus node; as part of the heart’s conductive system, the node is one of the main electrical regulators of cardiac rate and rhythm. Disruption to the sinus node’s structure can cause bradycardia. Researchers have used animal models combined with human stem cell-derived pacemaker cells to further understand this condition and set of effects.

Researchers using a type of pluripotent stem cell (hPSC) called human embryonic stem cells (hESC), have found that SARS-CoV-2 can readily infect pacemaker cells and induce a process known as ferroptosis [7]. Apoptosis, necrosis, autophagy, and other kinds of cell death are all distinct from ferroptosis, which is an iron-dependent cell death. The buildup of fatal lipid species resulting from lipid peroxidation defines the process of ferroptotic
cell death, which can be avoided by iron chelators — deferiprone, deferoxamine and tiny lipophilic antioxidants — ferrostatin and liproxstatin [8]. Researchers discovered that during the process of ferroptosis the human pacemaker cells produce angiotensin-converting enzyme 2 receptors and other complimentary components that facilitates and improves SARS-CoV-2 ability and frequency to enter cells, thus increasing infected cell rates by SARS-CoV-2 in human cells. These same SARS-CoV-2 infected cells also showed a significant rise in inflammatory immune gene activity. It is hypothesized that pacemaker cells infected with SARS-CoV-2 commence a self-destructive process of ferroptosis, an iron-dependent cell death and that commences early in COVID-19 patients within the sinus node, which explains the high incidence of bradycardia in patients.

Researchers have also investigated whether the damaging consequences of ferroptosis might be reversed by utilizing chelating agents; chemical molecules that closely attach to metal ions. The researchers examined the impact of chelating agents on the elimination of iron from the circulation and thus prevent the ferroptosis process. The chelating agents deferoxamine and imatinib were shown to prevent SARS-CoV-2-induced ferroptosis in the heart’s pacemaker cells [7].

From these research findings, it indicated that patients with COVID-19 could theoretically be treated with ferroptosis inhibitors to protect the sinoatrial (sinus node) cells, antiviral drugs that block the effects of SARS-CoV-2 infection in all cell types would be a preferred course of treatment. Although there is a worldwide medical push to protect all organs in both the severe course and the post-COVID-19 syndrome, other treatments do need to be considered.

The development of arrhythmias in the course of COVID-19 can have many reasons, but there is mounting research evidence demonstrating the involvement of pacemaker cells. This highlights the complexity of COVID-19 in the context of the cardiovascular system. Future research will need to be conducted into whether this phenomenon plays an important role among convalescents and patients struggling with the long-COVID-19 syndrome [9]. There is a need for further clinical and cellular research to clearly understand the mechanisms and the implementation of appropriate treatment strategies for the cardiac and other organs, both protective and symptomatic [10].

Acknowledgments
The study was supported by the Polish Society of Disaster Medicine.

Conflict of interest: None declared

References
1. Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 challenge for modern medicine. Cardiol J. 2020; 27(2): 175–183, doi: 10.5603/CJ.a2020.0055, indexed in Pubmed: 32286679.
2. Saban M, Shachar T. The silent effect of COVID-19 on emergency departments: How to avoid complacency? Disaster Emerg Med J. 2020, doi: 10.5603/demj.a2020.0035.
3. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: A systematic review and meta-analysis. Cardiol J. 2022; 29(1): 33–43, doi: 10.5603/CJ.a2021.0167, indexed in Pubmed: 34897631.
4. Nucera G, Chirico F, Rafique Z, et al. Need to update cardiological guidelines to prevent COVID-19 related myocardial infarction and ischemic stroke. Cardiol J. 2022; 29(1): 174–175, doi: 10.5603/CJ.a2021.0120, indexed in Pubmed: 34642925.
5. Touafchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021 [Epub ahead of print], doi: 10.1016/j.cmi.2021.02.013, indexed in Pubmed: 33647441.
6. Long B, Brady WJ, Bridwell RE, et al. Electrocardiographic manifestations of COVID-19. Am J Emerg Med. 2021; 41: 96–103, doi: 10.1016/j.ajem.2020.12.060, indexed in Pubmed: 33142365.
7. Han Y, Zhu J, Yang L, et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells. Circ Res. 2022; 120(7): 963–977, doi: 10.1161/CIRCRESAHA.121.320518, indexed in Pubmed: 35255712.
8. Yan HF, Zou T, Tao QZ, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021; 6(1): 49, doi: 10.1038/s41392-020-00428-9, indexed in Pubmed: 33536413.
9. Szarpak L, Pruc M, Filipiak KJ, et al. Myocarditis: A complication of COVID-19 and long-COVID-19 syndrome as a serious threat in modern cardiology. Cardiol J. 2022; 29(1): 178–179, doi: 10.5603/CJ.a2021.0155, indexed in Pubmed: 34811716.
10. Smereka J, Szarpak L, Filipiak K. Modern medicine in COVID-19 era. Disaster Emerg Med J. 2020, doi: 10.5603/demj.a2020.0012.